Polo-like kinase 1 inhibition in NSCLC: mechanism of action and emerging predictive biomarkers

References

• Cheng T-YD, Cramb SM, Baade PD, Youlden DR, Nwogu C, Reid ME. The international epidemiology of lung cancer: latest trends, disparities, and tumor characteristics. J Thorac Oncol. 2016;11:1653–1671. doi:10.1016/j.jtho.2016.05.02127364315
   PubMed Web of Science ®Google Scholar
• McPhail S, Johnson S, Greenberg D, Peake M, Rous B. Stage at diagnosis and early mortality from cancer in England. Br J Cancer. 2015;112(Suppl 1):S108–S115. doi:10.1038/bjc.2015.4925734389
   PubMed Web of Science ®Google Scholar
• Lake RJ, Jelinek WR. Cell cycle- and terminal differentiation-associated regulation of the mouse mRNA encoding a conserved mitotic protein kinase. Mol Cell Biol. 1993;13(12):7793–7801. doi:10.1128/mcb.13.12.77937902533
   PubMed Web of Science ®Google Scholar
• Holtrich U, Wolf G, Bräuninger A, et al. Induction and down-regulation of PLK, a human serine/threonine kinase expressed in proliferating cells and tumors. Proc Natl Acad Sci U S A. 1994;91(5):1736–1740. doi:10.1073/pnas.91.5.17368127874
   PubMed Web of Science ®Google Scholar
• Hamanaka R, Maloid S, Smith MR, O’Connell CD, Longo DL, Ferris DK. Cloning and characterization of human and murine homologues of the Drosophila polo serine-threonine kinase. Cell Growth Differ. 1994;5(3):249–257.8018557
   PubMedGoogle Scholar
• Liby K, Wu H, Ouyang B, Wu S, Chen J, Dai W. Identification of the human homologue of the early-growth response gene Snk, encoding a serum-inducible kinase. DNA Seq. 2001;11(6):527–533.11696980
   PubMed Web of Science ®Google Scholar
• Li B, Ouyang B, Pan H, et al. Prk, a cytokine-inducible human protein serine/threonine kinase whose expression appears to be down-regulated in lung carcinomas. J Biol Chem. 1996;271(32):19402–19408. doi:10.1074/jbc.271.32.194028702627
   PubMed Web of Science ®Google Scholar
• Martin C-A, Ahmad I, Klingseisen A, et al. Mutations in PLK4, encoding a master regulator of centriole biogenesis, cause microcephaly, growth failure and retinopathy. Nat Genet. 2014;46(12):1283–1292. doi:10.1038/ng.312225344692
   PubMed Web of Science ®Google Scholar
• de Cárcer G, Escobar B, Higuero AM, et al. Plk5, a polo box domain-only protein with specific roles in neuron differentiation and glioblastoma suppression. Mol Cell Biol. 2011;31(6):1225–1239. doi:10.1128/MCB.00607-1021245385
   PubMed Web of Science ®Google Scholar
• Strebhardt K, Ullrich A. Targeting polo-like kinase 1 for cancer therapy. Nat Rev Cancer. 2006;6(4):321–330. doi:10.1038/nrc184116557283
   PubMed Web of Science ®Google Scholar
• Hanks SK, Quinn AM, Hunter T. The protein kinase family: conserved features and deduced phylogeny of the catalytic domains. Science. 1988;241(4861):42–52.3291115
   PubMed Web of Science ®Google Scholar
• Elia AEH, Rellos P, Haire LF, et al. The molecular basis for phosphodependent substrate targeting and regulation of PLKs by the polo-box domain. Cell. 2003;115(1):83–95. doi:10.1016/S0092-8674(03)00725-614532005
   PubMed Web of Science ®Google Scholar
• Golsteyn RM, Mundt KE, Fry AM, Nigg EA. Cell cycle regulation of the activity and subcellular localization of PLK1, a human protein kinase implicated in mitotic spindle function. J Cell Biol. 1995;129(6):1617–1628. doi:10.1083/jcb.129.6.16177790358
   PubMed Web of Science ®Google Scholar
• Wolfe BA, Takaki T, Petronczki M, Glotzer M. Polo-like kinase 1 directs assembly of the HsCyk-4 RhoGAP/Ect2 RhoGEF complex to initiate cleavage furrow formation. PLoS Biol. 2009;7(5):e1000110. doi:10.1371/journal.pbio.100011019468300
   PubMed Web of Science ®Google Scholar
• Petronczki M, Glotzer M, Kraut N, Peters J-M. Polo-like kinase 1 triggers the initiation of cytokinesis in human cells by promoting recruitment of the RhoGEF Ect2 to the central spindle. Dev Cell. 2007;12(5):713–725. doi:10.1016/j.devcel.2007.03.01317488623
   PubMed Web of Science ®Google Scholar
• Moshe Y, Boulaire J, Pagano M, Hershko A. Role of Polo-like kinase in the degradation of early mitotic inhibitor 1, a regulator of the anaphase promoting complex/cyclosome. Proc Natl Acad Sci U S A. 2004;101(21):7937–7942. doi:10.1073/pnas.040244210115148369
   PubMed Web of Science ®Google Scholar
• Hansen DV, Loktev AV, Ban KH, Jackson PK. PLK1 regulates activation of the anaphase promoting complex by phosphorylating and triggering SCFbetaTrCP-dependent destruction of the APC Inhibitor Emi1. Mol Biol Cell. 2004;15(12):5623–5634. doi:10.1091/mbc.e04-07-059815469984
   PubMed Web of Science ®Google Scholar
• Yan W, Yu H, Li W, et al. PLK1 promotes the migration of human lung adenocarcinoma epithelial cells via STAT3 signaling. Oncol Lett. 2018;16(5):6801–6807. doi:10.3892/ol.2018.943730405824
   PubMed Web of Science ®Google Scholar
• Li H, Wang Y, Liu X. PLK1-dependent phosphorylation regulates functions of DNA topoisomerase IIalpha in cell cycle progression. J Biol Chem. 2008;283(10):6209–6221. doi:10.1074/jbc.M70900720018171681
   PubMed Web of Science ®Google Scholar
• Rizki A, Mott JD, Bissell MJ. Polo-like kinase 1 is involved in invasion through extracellular matrix. Cancer Res. 2007;67(23):11106–11110. doi:10.1158/0008-5472.CAN-07-234818056432
   PubMed Web of Science ®Google Scholar
• Wu Z-Q, Yang X, Weber G, Liu X. PLK1 phosphorylation of TRF1 is essential for its binding to telomeres. J Biol Chem. 2008;283(37):25503–25513. doi:10.1074/jbc.M80330420018625707
   PubMed Web of Science ®Google Scholar
• Toyoshima-Morimoto F, Taniguchi E, Shinya N, Iwamatsu A, Nishida E. Polo-like kinase 1 phosphorylates cyclin B1 and targets it to the nucleus during prophase. Nature. 2001;410(6825):215–220. doi:10.1038/3506561711242082
   PubMed Web of Science ®Google Scholar
• Seki A, Coppinger JA, Jang C-Y, Yates JR, Fang G. Bora and the kinase Aurora a cooperatively activate the kinase PLK1 and control mitotic entry. Science. 2008;320(5883):1655–1658. doi:10.1126/science.115742518566290
   PubMed Web of Science ®Google Scholar
• Macůrek L, Lindqvist A, Lim D, et al. Polo-like kinase-1 is activated by aurora A to promote checkpoint recovery. Nature. 2008;455(7209):119–123. doi:10.1038/nature0718518615013
   PubMed Web of Science ®Google Scholar
• Smith MR, Wilson ML, Hamanaka R, et al. Malignant transformation of mammalian cells initiated by constitutive expression of the polo-like kinase. Biochem Biophys Res Commun. 1997;234(2):397–405.9177283
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Polo-like kinase (PLK)1 depletion induces apoptosis in cancer cells. Proc Natl Acad Sci U S A. 2003;100(10):5789–5794. doi:10.1073/pnas.103152310012732729
   PubMed Web of Science ®Google Scholar
• Liu X, Erikson RL. Activation of Cdc2/cyclin B and inhibition of centrosome amplification in cells depleted of PLK1 by siRNA. Proc Natl Acad Sci U S A. 2002;99(13):8672–8676. doi:10.1073/pnas.13226959912077309
   PubMed Web of Science ®Google Scholar
• Spänkuch-Schmitt B, Bereiter-Hahn J, Kaufmann M, Strebhardt K. Effect of RNA silencing of polo-like kinase-1 (PLK1) on apoptosis and spindle formation in human cancer cells. J Natl Cancer Inst. 2002;94(24):1863–1877. doi:10.1093/jnci/94.24.186312488480
   PubMed Web of Science ®Google Scholar
• Spänkuch-Schmitt B, Wolf G, Solbach C, et al. Downregulation of human polo-like kinase activity by antisense oligonucleotides induces growth inhibition in cancer cells. Oncogene. 2002;21(20):3162–3171. doi:10.1038/sj.onc.120541212082631
   PubMed Web of Science ®Google Scholar
• Sumara I, Gimenez-Abian JF, Gerlich D, et al. Roles of polo-like kinase 1 in the assembly of functional mitotic spindles. Curr Biol. 2004;14(19):1712–1722. doi:10.1016/j.cub.2004.09.04915458642
   PubMed Web of Science ®Google Scholar
• Wolf G, Elez R, Doermer A, et al. Prognostic significance of polo-like kinase (PLK) expression in non-small cell lung cancer. Oncogene. 1997;14(5):543–549. doi:10.1038/sj.onc.12008629053852
   PubMed Web of Science ®Google Scholar
• Allera-Moreau C, Rouquette I, Lepage B, et al. DNA replication stress response involving PLK1, CDC6, POLQ, RAD51 and CLASPIN upregulation prognoses the outcome of early/mid-stage non-small cell lung cancer patients. Oncogenesis. 2012;1:e30. doi:10.1038/oncsis.2012.2923552402
   PubMed Web of Science ®Google Scholar
• Wang Z-X, Xue D, Liu Z-L, et al. Overexpression of polo-like kinase 1 and its clinical significance in human non-small cell lung cancer. Int J Biochem Cell Biol. 2012;44(1):200–210. doi:10.1016/j.biocel.2011.10.01722064247
   PubMed Web of Science ®Google Scholar
• Li H, Wang H, Sun Z, Guo Q, Shi H, Jia Y. The clinical and prognostic value of polo-like kinase 1 in lung squamous cell carcinoma patients: immunohistochemical analysis. Biosci Rep. 2017;37:BSR20170852. doi:10.1042/BSR20170852
   Web of Science ®Google Scholar
• Zhou Q, Su Y, Bai M. Effect of antisense RNA targeting Polo-like kinase 1 on cell growth in A549 lung cancer cells. J Huazhong Univ Sci Technol Med Sci. 2008;28(1):22–26. doi:10.1007/s11596-008-0106-918278450
   PubMedGoogle Scholar
• Cogswell JP, Brown CE, Bisi JE, Neill SD. Dominant-negative polo-like kinase 1 induces mitotic catastrophe independent of cdc25C function. Cell Growth Differ. 2000;11(12):615 http://cgd.aacrjournals.org/cgi/content/full/11/12/61511149596
   PubMedGoogle Scholar
• Kawata E, Ashihara E, Maekawa T. RNA interference against polo-like kinase-1 in advanced non-small cell lung cancers. J Clin Bioinforma. 2011;1(1):6. doi:10.1186/2043-9113-1-621884621
   PubMedGoogle Scholar
• Zhao X-Y, Nie C-L, Liang S-F, Yuan Z, Deng H-X, Wei Y-Q. Enhanced gemcitabine-mediated cell killing of human lung adenocarcinoma by vector-based RNA interference against PLK1. Biomed Pharmacother. 2012;66(8):597–602. doi:10.1016/j.biopha.2012.01.00323153503
   PubMed Web of Science ®Google Scholar
• Sinha RP, Häder D-P. UV-protectants in cyanobacteria. Plant Sci. 2008;174(3):278–289. doi:10.1016/j.plantsci.2007.12.004
   Web of Science ®Google Scholar
• Stevenson CS, Capper EA, Roshak AK, et al. The identification and characterization of the marine natural product scytonemin as a novel antiproliferative pharmacophore. J Pharmacol Exp Ther. 2002;303(2):858–866. doi:10.1124/jpet.102.03635012388673
   PubMed Web of Science ®Google Scholar
• Steegmaier M, Hoffmann M, Baum A, et al. BI 2536, a potent and selective inhibitor of polo-like kinase 1, inhibits tumor growth in vivo. Curr Biol. 2007;17(4):316–322. doi:10.1016/j.cub.2006.12.03717291758
   PubMed Web of Science ®Google Scholar
• Mross K, Frost A, Steinbild S, et al. Phase I dose escalation and pharmacokinetic study of BI 2536, a novel Polo-like kinase 1 inhibitor, in patients with advanced solid tumors. J Clin Oncol. 2008;26(34):5511–5517. doi:10.1200/JCO.2008.16.154718955456
   PubMed Web of Science ®Google Scholar
• Hofheinz R-D, Al-Batran S-E, Hochhaus A, et al. An open-label, phase I study of the polo-like kinase-1 inhibitor, BI 2536, in patients with advanced solid tumors. Clin Cancer Res. 2010;16(18):4666–4674. doi:10.1158/1078-0432.CCR-10-031820682708
   PubMed Web of Science ®Google Scholar
• Sebastian M, Reck M, Waller CF, et al. The efficacy and safety of BI 2536, a novel PLK-1 inhibitor, in patients with stage IIIB/IV non-small cell lung cancer who had relapsed after, or failed, chemotherapy: results from an open-label, randomized phase II clinical trial. J Thorac Oncol. 2010;5(7):1060–1067. doi:10.1097/JTO.0b013e3181d95dd420526206
   PubMed Web of Science ®Google Scholar
• Ellis PM, Chu QS, Leighl N, et al. A phase I open-label dose-escalation study of intravenous BI 2536 together with pemetrexed in previously treated patients with non-small-cell lung cancer. Clin Lung Cancer. 2013;14(1):19–27. doi:10.1016/j.cllc.2012.04.00322658814
   PubMed Web of Science ®Google Scholar
• Rudolph D, Steegmaier M, Hoffmann M, et al. BI 6727, a Polo-like kinase inhibitor with improved pharmacokinetic profile and broad antitumor activity. Clin Cancer Res. 2009;15(9):3094–3102. doi:10.1158/1078-0432.CCR-08-244519383823
   PubMed Web of Science ®Google Scholar
• Ferrarotto R, Goonatilake R, Yoo SY, et al. Epithelial-mesenchymal transition predicts polo-like kinase 1 inhibitor-mediated apoptosis in non-small cell lung cancer. Clin Cancer Res. 2016;22(7):1674–1686. doi:10.1158/1078-0432.CCR-14-289026597303
   PubMed Web of Science ®Google Scholar
• Crystal AS, Shaw AT, Sequist LV, et al. Patient-derived models of acquired resistance can identify effective drug combinations for cancer. Science. 2014;346(6216):1480–1486. doi:10.1126/science.125472125394791
   PubMed Web of Science ®Google Scholar
• Wang Y, Singh R, Wang L, et al. Polo-like kinase 1 inhibition diminishes acquired resistance to epidermal growth factor receptor inhibition in non-small cell lung cancer with T790M mutations. Oncotarget. 2016;7(30):47998–48010. doi:10.18632/oncotarget.1033227384992
   PubMedGoogle Scholar
• Wang Y, Wu L, Yao Y, Lu G, Xu L, Zhou J. Polo-like kinase 1 inhibitor BI 6727 induces DNA damage and exerts strong antitumor activity in small cell lung cancer. Cancer Lett. 2018;436:1–9. doi:10.1016/j.canlet.2018.08.00730118839
   PubMed Web of Science ®Google Scholar
• Gil T, Schöffski P, Awada A, et al. Final analysis of a phase I single dose-escalation study of the novel polo-like kinase 1 inhibitor BI 6727 in patients with advanced solid tumors. J Clin Oncol. 2010;28(15_suppl):3061. doi:10.1200/jco.2010.28.15_suppl.306120479398
   PubMed Web of Science ®Google Scholar
• Schöffski P, Awada A, Dumez H, et al. A phase I, dose-escalation study of the novel Polo-like kinase inhibitor volasertib (BI 6727) in patients with advanced solid tumours. Eur J Cancer. 2012;48(2):179–186. doi:10.1016/j.ejca.2011.11.00122119200
   PubMed Web of Science ®Google Scholar
• Lin -C-C, Su W-C, Yen C-J, et al. A phase I study of two dosing schedules of volasertib (BI 6727), an intravenous polo-like kinase inhibitor, in patients with advanced solid malignancies. Br J Cancer. 2014;110(10):2434–2440. doi:10.1038/bjc.2014.19524755882
   PubMed Web of Science ®Google Scholar
• Machiels J-P, Peeters M, Herremans C, et al. A phase I study of volasertib combined with afatinib, in advanced solid tumors. Cancer Chemother Pharmacol. 2015;76(4):843–851. doi:10.1007/s00280-015-2860-226349473
   PubMed Web of Science ®Google Scholar
• Nokihara H, Yamada Y, Fujiwara Y, et al. Phase I trial of volasertib, a Polo-like kinase inhibitor, in Japanese patients with advanced solid tumors. Invest New Drugs. 2016;34(1):66–74. doi:10.1007/s10637-015-0300-026627079
   PubMed Web of Science ®Google Scholar
• de Braud F, Cascinu S, Spitaleri G, et al. A phase I, dose-escalation study of volasertib combined with nintedanib in advanced solid tumors. Ann Oncol. 2015;26(11):2341–2346. doi:10.1093/annonc/mdv35426395347
   PubMed Web of Science ®Google Scholar
• Gumireddy K, Reddy MVR, Cosenza SC, et al. ON01910, a non-ATP-competitive small molecule inhibitor of PLK1, is a potent anticancer agent. Cancer Cell. 2005;7(3):275–286. doi:10.1016/j.ccr.2005.02.00915766665
   PubMed Web of Science ®Google Scholar
• Prasad A, Khudaynazar N, Tantravahi RV, Gillum AM, Hoffman BS. ON 01910.Na (rigosertib) inhibits PI3K/Akt pathway and activates oxidative stress signals in head and neck cancer cell lines. Oncotarget. 2016;7(48):79388–79400. doi:10.18632/oncotarget.1269227764820
   PubMedGoogle Scholar
• Xu F, He Q, Li X, et al. Rigosertib as a selective anti-tumor agent can ameliorate multiple dysregulated signaling transduction pathways in high-grade myelodysplastic syndrome. Sci Rep. 2014;4:7310. doi:10.1038/srep0731025472472
   PubMed Web of Science ®Google Scholar
• Ohnuma T, Lehrer D, Ren C, et al. Phase 1 study of intravenous rigosertib (ON 01910.Na), a novel benzyl styryl sulfone structure producing G2/M arrest and apoptosis, in adult patients with advanced cancer. Am J Cancer Res. 2013;3(3):323–338.23841031
   PubMed Web of Science ®Google Scholar
• Bowles DW, Diamond JR, Lam ET, et al. Phase I study of oral rigosertib (ON 01910.Na), a dual inhibitor of the PI3K and PLK1 pathways, in adult patients with advanced solid malignancies. Clin Cancer Res. 2014;20(6):1656–1665. doi:10.1158/1078-0432.CCR-13-250624493827
   PubMed Web of Science ®Google Scholar
• Garland LL, Taylor C, Pilkington DL, Cohen JL, von Hoff DD. A phase I pharmacokinetic study of HMN-214, a novel oral stilbene derivative with polo-like kinase-1-interacting properties, in patients with advanced solid tumors. Clin Cancer Res. 2006;12(17):5182–5189. doi:10.1158/1078-0432.CCR-06-021416951237
   PubMed Web of Science ®Google Scholar
• Weiss GJ, Jameson G, von Hoff DD, et al. Phase I dose escalation study of NMS-1286937, an orally available Polo-Like Kinase 1 inhibitor, in patients with advanced or metastatic solid tumors. Invest New Drugs. 2018;36(1):85–95. doi:10.1007/s10637-017-0491-728726132
   PubMed Web of Science ®Google Scholar
• Duffey MO, Vos TJ, Adams R, et al. Discovery of a potent and orally bioavailable benzolactam-derived inhibitor of Polo-like kinase 1 (MLN0905). J Med Chem. 2012;55(1):197–208. doi:10.1021/jm201117222070629
   PubMed Web of Science ®Google Scholar
• Wang -N-N, Li Z-H, Zhao H, et al. Molecular targeting of the oncoprotein PLK1 in pediatric acute myeloid leukemia: RO3280, a novel PLK1 inhibitor, induces apoptosis in leukemia cells. Int J Mol Sci. 2015;16(1):1266–1292. doi:10.3390/ijms1601126625574601
   PubMed Web of Science ®Google Scholar
• Mason JM, Lin DCC, Wei X, et al. Functional characterization of CFI-400945, a Polo-like kinase 4 inhibitor, as a potential anticancer agent. Cancer Cell. 2014;26(2):163–176. doi:10.1016/j.ccr.2014.05.00625043604
   PubMed Web of Science ®Google Scholar
• Moureau S, Pohler E, Kroboth K, et al. Therapeutic potential of novel PLK1 inhibitor CYC140 in esophageal cancer and acute leukemia. European Journal of Cancer 2016;69:S117. doi:10.1016/S0959-8049(16)32948-3
   Google Scholar
• Elia AEH, Cantley LC, Yaffe MB. Proteomic screen finds pSer/pThr-binding domain localizing PLK1 to mitotic substrates. Science. 2003;299(5610):1228–1231. doi:10.1126/science.107907912595692
   PubMed Web of Science ®Google Scholar
• Yun S-M, Moulaei T, Lim D, et al. Structural and functional analyses of minimal phosphopeptides targeting the polo-box domain of polo-like kinase 1. Nat Struct Mol Biol. 2009;16(8):876–882. doi:10.1038/nsmb.162819597481
   PubMed Web of Science ®Google Scholar
• Reindl W, Strebhardt K, Berg T. A high-throughput assay based on fluorescence polarization for inhibitors of the polo-box domain of polo-like kinase 1. Anal Biochem. 2008;383(2):205–209. doi:10.1016/j.ab.2008.08.01418793607
   PubMed Web of Science ®Google Scholar
• Yuan J, Sanhaji M, Krämer A, et al. Polo-box domain inhibitor poloxin activates the spindle assembly checkpoint and inhibits tumor growth in vivo. Am J Pathol. 2011;179(4):2091–2099. doi:10.1016/j.ajpath.2011.06.03121839059
   PubMed Web of Science ®Google Scholar
• Scharow A, Raab M, Saxena K, et al. Optimized PLK1 PBD inhibitors based on poloxin induce mitotic arrest and apoptosis in tumor cells. ACS Chem Biol. 2015;10(11):2570–2579. doi:10.1021/acschembio.5b0056526279064
   PubMed Web of Science ®Google Scholar
• Reindl W, Yuan J, Krämer A, Strebhardt K, Berg T. A pan-specific inhibitor of the polo-box domains of polo-like kinases arrests cancer cells in mitosis. Chembiochem. 2009;10(7):1145–1148. doi:10.1002/cbic.20090005919350612
   PubMed Web of Science ®Google Scholar
• Srinivasrao G, Park J-E, Kim S, et al. Design and synthesis of a cell-permeable, drug-like small molecule inhibitor targeting the polo-box domain of polo-like kinase 1. PLoS One. 2014;9(9):e107432. doi:10.1371/journal.pone.010743225211362
   PubMed Web of Science ®Google Scholar
• Narvaez AJ, Ber S, Crooks A, et al. Modulating protein-protein interactions of the mitotic polo-like kinases to target mutant KRAS. Cell Chem Biol. 2017;24(8):1017–1028.e7. doi:10.1016/j.chembiol.2017.07.00928807782
   PubMed Web of Science ®Google Scholar
• Shan H-M, Shi Y, Quan J. Identification of green tea catechins as potent inhibitors of the polo-box domain of polo-like kinase 1. ChemMedChem. 2015;10(1):158–163. doi:10.1002/cmdc.20140228425196850
   PubMed Web of Science ®Google Scholar
• Laurie SA, Miller VA, Grant SC, Kris MG, Ng KK. Phase I study of green tea extract in patients with advanced lung cancer. Cancer Chemother Pharmacol. 2005;55(1):33–38. doi:10.1007/s00280-004-0859-115309507
   PubMed Web of Science ®Google Scholar
• Guan R, Tapang P, Leverson JD, Albert D, Giranda VL, Luo Y. Small interfering RNA-mediated Polo-like kinase 1 depletion preferentially reduces the survival of p53-defective, oncogenic transformed cells and inhibits tumor growth in animals. Cancer Res. 2005;65(7):2698–2704. doi:10.1158/0008-5472.CAN-04-213115805268
   PubMed Web of Science ®Google Scholar
• Anderson RT, Keysar SB, Bowles DW, et al. The dual pathway inhibitor rigosertib is effective in direct patient tumor xenografts of head and neck squamous cell carcinomas. Mol Cancer Ther. 2013;12(10):1994–2005. doi:10.1158/1535-7163.MCT-13-020623873848
   PubMed Web of Science ®Google Scholar
• Degenhardt Y, Greshock J, Laquerre S, et al. Sensitivity of cancer cells to PLK1 inhibitor GSK461364A is associated with loss of p53 function and chromosome instability. Mol Cancer Ther. 2010;9(7):2079–2089. doi:10.1158/1535-7163.MCT-10-009520571075
   PubMed Web of Science ®Google Scholar
• McKenzie L, King S, Marcar L, et al. p53-dependent repression of polo-like kinase-1 (PLK1). Cell Cycle. 2010;9(20):4200–4212. doi:10.4161/cc.9.20.1353220962589
   PubMed Web of Science ®Google Scholar
• Danovi D, Folarin A, Gogolok S, et al. A high-content small molecule screen identifies sensitivity of glioblastoma stem cells to inhibition of polo-like kinase 1. PLoS One. 2013;8(10):e77053. doi:10.1371/journal.pone.007705324204733
   PubMed Web of Science ®Google Scholar
• Liu X, Lei M, Erikson RL. Normal cells, but not cancer cells, survive severe PLK1 depletion. Mol Cell Biol. 2006;26(6):2093–2108. doi:10.1128/MCB.26.6.2093-2108.200616507989
   PubMed Web of Science ®Google Scholar
• Sur S, Pagliarini R, Bunz F, et al. A panel of isogenic human cancer cells suggests a therapeutic approach for cancers with inactivated p53. Proc Natl Acad Sci U S A. 2009;106(10):3964–3969. doi:10.1073/pnas.081333310619225112
   PubMed Web of Science ®Google Scholar
• Smith L, Farzan R, Ali S, Buluwela L, Saurin AT, Meek DW. The responses of cancer cells to PLK1 inhibitors reveal a novel protective role for p53 in maintaining centrosome separation. Sci Rep. 2017;7(1):16115. doi:10.1038/s41598-017-16394-229170437
   PubMed Web of Science ®Google Scholar
• Steels E, Paesmans M, Berghmans T, et al. Role of p53 as a prognostic factor for survival in lung cancer: a systematic review of the literature with a meta-analysis. Eur Respir J. 2001;18(4):705–719. doi:10.1183/09031936.01.0006220111716177
   PubMed Web of Science ®Google Scholar
• Ferrer I, Zugazagoitia J, Herbertz S, John W, Paz-Ares L, Schmid-Bindert G. KRAS-Mutant non-small cell lung cancer: from biology to therapy. Lung Cancer. 2018;124:53–64. doi:10.1016/j.lungcan.2018.07.01330268480
   PubMed Web of Science ®Google Scholar
• Luo J, Emanuele MJ, Li D, et al. A genome-wide RNAi screen identifies multiple synthetic lethal interactions with the Ras oncogene. Cell. 2009;137(5):835–848. doi:10.1016/j.cell.2009.05.00619490893
   PubMed Web of Science ®Google Scholar
• Athuluri-Divakar SK, Vasquez-Del Carpio R, Dutta K, et al. A small molecule RAS-mimetic disrupts RAS association with effector proteins to block signaling. Cell. 2016;165(3):643–655. doi:10.1016/j.cell.2016.03.04527104980
   PubMed Web of Science ®Google Scholar
• Mendoza MC, Er EE, Blenis J. The Ras-ERK and PI3K-mTOR pathways: cross-talk and compensation. Trends Biochem Sci. 2011;36(6):320–328. doi:10.1016/j.tibs.2011.03.00621531565
   PubMed Web of Science ®Google Scholar
• Liu XS, Song B, Elzey BD, et al. Polo-like kinase 1 facilitates loss of Pten tumor suppressor-induced prostate cancer formation. J Biol Chem. 2011;286(41):35795–35800. doi:10.1074/jbc.C111.26905021890624
   PubMed Web of Science ®Google Scholar
• Dietrich P, Freese K, Mahli A, Thasler WE, Hellerbrand C, Bosserhoff AK. Combined effects of PLK1 and RAS in hepatocellular carcinoma reveal rigosertib as promising novel therapeutic “dual-hit” option. Oncotarget. 2018;9(3):3605–3618. doi:10.18632/oncotarget.2318829423069
   PubMedGoogle Scholar
• Ye C, Wang J, Wu P, et al. Prognostic role of cyclin B1 in solid tumors: a meta-analysis. Oncotarget. 2016;8(2):2224–2232. doi:10.18632/oncotarget.13653
   Google Scholar
• Soria JC, Jang SJ, Khuri FR, et al. Overexpression of cyclin B1 in early-stage non-small cell lung cancer and its clinical implication. Cancer Res. 2000;60(15):4000–4004.10945597
   PubMed Web of Science ®Google Scholar
• Cooper WA, Kohonen-Corish MRJ, McCaughan B, Kennedy C, Sutherland RL, Lee CS. Expression and prognostic significance of cyclin B1 and cyclin A in non-small cell lung cancer. Histopathology. 2009;55(1):28–36. doi:10.1111/j.1365-2559.2009.03331.x19614764
   PubMed Web of Science ®Google Scholar
• Arinaga M, Noguchi T, Takeno S, et al. Clinical implication of cyclin B1 in non-small cell lung cancer. Oncol Rep. 2003;10(5):1381–1386.12883711
   PubMed Web of Science ®Google Scholar
• Yoshida T, Tanaka S, Mogi A, Shitara Y, Kuwano H. The clinical significance of Cyclin B1 and Wee1 expression in non-small-cell lung cancer. Ann Oncol. 2004;15(2):252–256. doi:10.1093/annonc/mdh07314760118
   PubMed Web of Science ®Google Scholar
• Jimeno A, Chan A, Cusatis G, et al. Evaluation of the novel mitotic modulator ON 01910.Na in pancreatic cancer and preclinical development of an ex vivo predictive assay. Oncogene. 2009;28(4):610. doi:10.1038/onc.2008.42419029951
   PubMed Web of Science ®Google Scholar
• Olnes MJ, Shenoy A, Weinstein B, et al. Directed therapy for patients with myelodysplastic syndromes (MDS) by suppression of cyclin D1 with ON 01910.Na. Leuk Res. 2012;36(8):982–989. doi:10.1016/j.leukres.2012.04.00222524974
   PubMed Web of Science ®Google Scholar
• Kalimutho M, Sinha D, Jeffery J, et al. CEP55 is a determinant of cell fate during perturbed mitosis in breast cancer. EMBO Mol Med. 2018;10:9. doi:10.15252/emmm.201708566
   Web of Science ®Google Scholar
• Jiang C, Zhang Y, Li Y, et al. High CEP55 expression is associated with poor prognosis in non-small-cell lung cancer. OTT. 2018;11:4979–4990. doi:10.2147/OTT.S165750
   Web of Science ®Google Scholar
• Zhang M, Singh R, Peng S, et al. Mutations of the LIM protein AJUBA mediate sensitivity of head and neck squamous cell carcinoma to treatment with cell-cycle inhibitors. Cancer Lett. 2017;392:71–82. doi:10.1016/j.canlet.2017.01.02428126323
   PubMed Web of Science ®Google Scholar
• Legras A, Pécuchet N, Imbeaud S, et al. Epithelial-to-mesenchymal transition and MicroRNAs in lung cancer. Cancers (Basel). 2017;9:8. doi:10.3390/cancers9080101
   Web of Science ®Google Scholar
• Heery R, Finn SP, Cuffe S, Gray SG. Long non-coding RNAs: key regulators of epithelial-mesenchymal transition, tumour drug resistance and cancer stem cells. Cancers (Basel). 2017;9:4. doi:10.3390/cancers9040038
   PubMed Web of Science ®Google Scholar
• Shibue T, Weinberg RA. EMT, CSCs, and drug resistance: the mechanistic link and clinical implications. Nat Rev Clin Oncol. 2017;14(10):611–629. doi:10.1038/nrclinonc.2017.4428397828
   PubMed Web of Science ®Google Scholar
• Du B, Shim JS. Targeting Epithelial-Mesenchymal Transition (EMT) to overcome drug resistance in cancer. Molecules. 2016;21:7. doi:10.3390/molecules21070965
   Web of Science ®Google Scholar
• Brozovic A. The relationship between platinum drug resistance and epithelial-mesenchymal transition. Arch Toxicol. 2017;91(2):605–619. doi:10.1007/s00204-016-1912-728032148
   PubMed Web of Science ®Google Scholar
• Xiao D, He J. Epithelial mesenchymal transition and lung cancer. J Thorac Dis. 2010;2(3):154–159. doi:10.3978/j.issn.2072-1439.2010.02.03.722263037
   PubMedGoogle Scholar
• Hashida S, Yamamoto H, Shien K, et al. Acquisition of cancer stem cell-like properties in non-small cell lung cancer with acquired resistance to afatinib. Cancer Sci. 2015;106(10):1377–1384. doi:10.1111/cas.1274926202045
   PubMed Web of Science ®Google Scholar
• Singh R, Peng S, Viswanath P, et al. Non-canonical cMet regulation by vimentin mediates PLK1 inhibitor-induced apoptosis. EMBO Mol Med. 2019;11:5. doi:10.15252/emmm.201809960
   Web of Science ®Google Scholar
• Breitenbuecher F, von Pawel J, Sebastian M, et al. Comprehensive biomarker analyses in patients with advanced or metastatic non-small cell lung cancer prospectively treated with the polo-like kinase 1 inhibitor BI2536. Oncol Res Treat. 2017;40(7–8):435–439. doi:10.1159/00047550328628916
   PubMed Web of Science ®Google Scholar